| 24 |
[AACR] Dong-A ST and Aptis present 9 anticancer candidates, including ADCs
|
2026-05-18 |
131 |
| 23 |
Dong-A ST secures Canadian approval for Stelara biosimilar ‘Imuldosa’
|
2026-05-18 |
111 |
| 22 |
Dong-A ST, Accord launch Stelara biosimilar Imuldosa in US
|
2025-11-14 |
933 |
| 21 |
Dong-A ST, SK bioscience, and Onconic Therapeutics are among 7 Innovative Pharmaceutical Companies
|
2025-01-08 |
1549 |
| 20 |
Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA
|
2025-01-08 |
1457 |
| 19 |
CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to STELARA®
|
2024-10-23 |
1667 |
| 18 |
US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®
|
2024-10-23 |
1529 |
| 17 |
Dong-A ST's ECG Monitoring Platform Hicardi+ H100 Receives U.S. FDA Approval
|
2024-09-30 |
1154 |
| 16 |
Dong-A ST and its subsidiary to codevelop long-acting obesity drug with ImmunoForge
|
2024-08-20 |
1313 |
| 15 |
Dong-A ST Presents Preclinical Results of Tau-Targeting Dementia Treatment ‘DA-7503’ at AAIC
|
2024-08-08 |
1696 |
